Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer Prolia to treat postmenopausal women with osteoporosis Xgeva for skeletal-related events prevention Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease Aranesp to treat a lower-than-normal number of red blood cells and anemia KYPROLIS to treat patients with relapsed or refractory multiple myeloma and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG UCB Bayer HealthCare LLC BeiGene, Ltd. and Eli Lilly and Company. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.